• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

35.73 -0.34 (-0.96%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 167,147
Open 36.42
Bid (Size) 35.52 (200)
Ask (Size) 35.95 (300)
Prev. Close 36.08
Today's Range 34.97 - 37.61
52wk Range 12.24 - 37.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+113.1%
+113.1%
1 Month
+20.1%
+20.1%
3 Month
+71.6%
+71.6%
6 Month
+103.4%
+103.4%
1 Year
+94.8%
+94.8%

More News

Read More
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
June 08, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
May 31, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
May 15, 2026
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
May 04, 2026
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 01, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
April 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 02, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
January 09, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
January 05, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
December 16, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
December 04, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 29, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MapLight Therapeutics, Inc. - Common Stock publicly traded?
Yes, MapLight Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MapLight Therapeutics, Inc. - Common Stock trade on?
MapLight Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MapLight Therapeutics, Inc. - Common Stock?
The ticker symbol for MapLight Therapeutics, Inc. - Common Stock is MPLT on the Nasdaq Stock Market
What is the current price of MapLight Therapeutics, Inc. - Common Stock?
The current price of MapLight Therapeutics, Inc. - Common Stock is 35.73
When was MapLight Therapeutics, Inc. - Common Stock last traded?
The last trade of MapLight Therapeutics, Inc. - Common Stock was at 07/02/26 02:16 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap